TG Therapeutics Sets Nov. 9 Earnings Call as BRIUMVI Expands Its Global Footprint in MS
Market Chameleon (Mon, 2-Nov 8:45 AM)
TG Therapeutics spotlights Phase 1 azer-cel data in progressive MS, with 89% stable or improved disability at Day 90
Market Chameleon (Mon, 26-Oct 8:56 AM)